Login to Your Account

Other News To Note

Friday, November 18, 2011
• Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said the European Medicines Agency accepted the marketing authorization application filing for Nuedexta (dextromethorphan HBr and quinidine sulfate) to treat pseudobulbar affect. Nuedexta gained approval in the U.S. in October 2010.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription